AbbVie has scored a major reduction of damages in a retrial of an AndroGel liability case. After a judge nixed the initial verdict of $150 million and sent the case back for retrial, a jury this week ...
Are you a male experiencing symptoms of low testosterone such as weight gain and a high-pitched voice? If so, you may want to look into a product by the name of AndroGel. This testosterone gel has ...
AbbVie has suffered its second big AndroGel loss in court. On Thursday, a federal jury ordered the drugmaker to pay more than $140 million to a plaintiff who had a heart attack on the testosterone med ...
Q: Do men go through menopause? My interior body temperature is normal, but my exterior body temperature is hot. I saw an endocrinologist, and all my tests were normal. I suggested to my doctor that I ...
ATLANTA (CN) - Drugmakers cannot dismiss antitrust claims stemming from their multimillion-dollar settlements to eliminate competing generic drugs, a federal judge ruled. In the 1990s, Solvay ...
AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, ...
In a split decision, a federal jury in Chicago ordered AbbVie to pay $150 million in punitive damages for fraudulently misrepresenting the risks of its AndroGel testosterone replacement drug. But at ...
ATLANTA (CN) – A federal judge dismissed the remaining claims in a nearly 10-year-old dispute over competition on AndroGel, a drug that boosts testosterone production. In the 1990s, Unimed ...
In late July, an Illinois jury came to a bizarre verdict in a case over an alleged link between heart attacks and AndroGel, a gel product used for treating low testosterone (or “low T”). The jury ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results